Business · 21/07/1997Updated: 10/17/2026 · 1 min read
FDA Determines Regulatory Review Period for ProstaScint Patent Extension
Summary
The US Food and Drug Administration (FDA) has officially confirmed the regulatory review period for ProstaScint, a human biologic product, in order to extend its patent, as required by law.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →